CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kane Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kane Biotech Inc
162-196 Innovation Dr
Phone: (204) 500-0751p:204 500-0751 WINNIPEG, MB  R3T 6C5  Canada Ticker: KNEKNE

Business Summary
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies and products, which includes DispersinB, Aledex, bluestem, bluestem, Coactiv+, Coactiv+, goldstem, silkstem, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. The Company's other products in the early development stage includes Coactiv+, antimicrobial hydrogel for use in chronic wounds, Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202112/31/2020Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Mark H.Nawacki 52 1/1/2020 10/8/2014
President, Chief Executive Officer, Director MarcEdwards 9/10/2018 9/10/2018
Chief Financial Officer Raymond D.Dupuis 9/5/2017 9/5/2017
8 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 114,813,535 (As of 9/30/2021)
Stock Exchange: CVE
Fax Number: (204) 500-0751
Email Address: info@kanebiotech.com


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 30, 2021